Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine

Romano Arcieri, Elena A P Germinario, Maurizio Bonati, Gabriele Masi, Alessandro Zuddas, Stefano Vella, Flavia Chiarotti, Pietro Panei

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. Methods: This study was an open, prospective, observational study of youth with ADHD treated with atomoxetine (ATX) and methylphenidate (MPH). Measurements of blood pressure and heart rate, and electrocardiogram (ECG) assessment were performed at baseline and at regular intervals up to 24 months. Results: By June 2010, 1758 youth were enrolled in the Italian ADHD National Registry. Statistically significant increases were observed in cardiovascular measures: in the MPH group after 6 months in heart rate (+2.01, p=0.01); in the ATX group after 6 months in diastolic pressure (+1.60, p=0.01) and in heart rate (+2.93, p=0.001), and after 12 months in heart rate (+3.26, p=0.003). Compared with the baseline, 59 patients had an alteration of ECG during the follow-up period. Although at 12 months, the probability of detecting an abnormal ECG was higher in the MPH group than in the ATX group, only 2 out of 30 cases at 6 months with altered ECG were considered to have experienced serious adverse events. One case was treated with ATX and one with MPH, and arrhythmia was the detected abnormality. Conclusions: Treatment with MPH and ATX in youth appears to have a small but significant impact on the cardiovascular system. The long-term impact of these medications is unknown. Several clinically meaningless ECG alterations were observed mostly in MPH-treated youth. We therefore suggest evaluating cardiovascular risks at baseline.

Original languageEnglish
Pages (from-to)423-431
Number of pages9
JournalJournal of Child and Adolescent Psychopharmacology
Volume22
Issue number6
DOIs
Publication statusPublished - Dec 1 2012

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Electrocardiography
Heart Rate
Blood Pressure
Cardiovascular Agents
Cardiovascular System
Italy
Observational Studies
Registries
Atomoxetine Hydrochloride
Cardiac Arrhythmias
Prospective Studies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. / Arcieri, Romano; Germinario, Elena A P; Bonati, Maurizio; Masi, Gabriele; Zuddas, Alessandro; Vella, Stefano; Chiarotti, Flavia; Panei, Pietro.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 22, No. 6, 01.12.2012, p. 423-431.

Research output: Contribution to journalArticle

Arcieri, Romano ; Germinario, Elena A P ; Bonati, Maurizio ; Masi, Gabriele ; Zuddas, Alessandro ; Vella, Stefano ; Chiarotti, Flavia ; Panei, Pietro. / Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. In: Journal of Child and Adolescent Psychopharmacology. 2012 ; Vol. 22, No. 6. pp. 423-431.
@article{a908a8ce66284f52a96686fd1c77fdd5,
title = "Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine",
abstract = "Objective: The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. Methods: This study was an open, prospective, observational study of youth with ADHD treated with atomoxetine (ATX) and methylphenidate (MPH). Measurements of blood pressure and heart rate, and electrocardiogram (ECG) assessment were performed at baseline and at regular intervals up to 24 months. Results: By June 2010, 1758 youth were enrolled in the Italian ADHD National Registry. Statistically significant increases were observed in cardiovascular measures: in the MPH group after 6 months in heart rate (+2.01, p=0.01); in the ATX group after 6 months in diastolic pressure (+1.60, p=0.01) and in heart rate (+2.93, p=0.001), and after 12 months in heart rate (+3.26, p=0.003). Compared with the baseline, 59 patients had an alteration of ECG during the follow-up period. Although at 12 months, the probability of detecting an abnormal ECG was higher in the MPH group than in the ATX group, only 2 out of 30 cases at 6 months with altered ECG were considered to have experienced serious adverse events. One case was treated with ATX and one with MPH, and arrhythmia was the detected abnormality. Conclusions: Treatment with MPH and ATX in youth appears to have a small but significant impact on the cardiovascular system. The long-term impact of these medications is unknown. Several clinically meaningless ECG alterations were observed mostly in MPH-treated youth. We therefore suggest evaluating cardiovascular risks at baseline.",
author = "Romano Arcieri and Germinario, {Elena A P} and Maurizio Bonati and Gabriele Masi and Alessandro Zuddas and Stefano Vella and Flavia Chiarotti and Pietro Panei",
year = "2012",
month = "12",
day = "1",
doi = "10.1089/cap.2012.0014",
language = "English",
volume = "22",
pages = "423--431",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine

AU - Arcieri, Romano

AU - Germinario, Elena A P

AU - Bonati, Maurizio

AU - Masi, Gabriele

AU - Zuddas, Alessandro

AU - Vella, Stefano

AU - Chiarotti, Flavia

AU - Panei, Pietro

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Objective: The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. Methods: This study was an open, prospective, observational study of youth with ADHD treated with atomoxetine (ATX) and methylphenidate (MPH). Measurements of blood pressure and heart rate, and electrocardiogram (ECG) assessment were performed at baseline and at regular intervals up to 24 months. Results: By June 2010, 1758 youth were enrolled in the Italian ADHD National Registry. Statistically significant increases were observed in cardiovascular measures: in the MPH group after 6 months in heart rate (+2.01, p=0.01); in the ATX group after 6 months in diastolic pressure (+1.60, p=0.01) and in heart rate (+2.93, p=0.001), and after 12 months in heart rate (+3.26, p=0.003). Compared with the baseline, 59 patients had an alteration of ECG during the follow-up period. Although at 12 months, the probability of detecting an abnormal ECG was higher in the MPH group than in the ATX group, only 2 out of 30 cases at 6 months with altered ECG were considered to have experienced serious adverse events. One case was treated with ATX and one with MPH, and arrhythmia was the detected abnormality. Conclusions: Treatment with MPH and ATX in youth appears to have a small but significant impact on the cardiovascular system. The long-term impact of these medications is unknown. Several clinically meaningless ECG alterations were observed mostly in MPH-treated youth. We therefore suggest evaluating cardiovascular risks at baseline.

AB - Objective: The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. Methods: This study was an open, prospective, observational study of youth with ADHD treated with atomoxetine (ATX) and methylphenidate (MPH). Measurements of blood pressure and heart rate, and electrocardiogram (ECG) assessment were performed at baseline and at regular intervals up to 24 months. Results: By June 2010, 1758 youth were enrolled in the Italian ADHD National Registry. Statistically significant increases were observed in cardiovascular measures: in the MPH group after 6 months in heart rate (+2.01, p=0.01); in the ATX group after 6 months in diastolic pressure (+1.60, p=0.01) and in heart rate (+2.93, p=0.001), and after 12 months in heart rate (+3.26, p=0.003). Compared with the baseline, 59 patients had an alteration of ECG during the follow-up period. Although at 12 months, the probability of detecting an abnormal ECG was higher in the MPH group than in the ATX group, only 2 out of 30 cases at 6 months with altered ECG were considered to have experienced serious adverse events. One case was treated with ATX and one with MPH, and arrhythmia was the detected abnormality. Conclusions: Treatment with MPH and ATX in youth appears to have a small but significant impact on the cardiovascular system. The long-term impact of these medications is unknown. Several clinically meaningless ECG alterations were observed mostly in MPH-treated youth. We therefore suggest evaluating cardiovascular risks at baseline.

UR - http://www.scopus.com/inward/record.url?scp=84871226888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871226888&partnerID=8YFLogxK

U2 - 10.1089/cap.2012.0014

DO - 10.1089/cap.2012.0014

M3 - Article

C2 - 23362511

AN - SCOPUS:84871226888

VL - 22

SP - 423

EP - 431

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 6

ER -